WO2006039281A2 - Produit et procede de prevention du cancer de la peau - Google Patents

Produit et procede de prevention du cancer de la peau Download PDF

Info

Publication number
WO2006039281A2
WO2006039281A2 PCT/US2005/034619 US2005034619W WO2006039281A2 WO 2006039281 A2 WO2006039281 A2 WO 2006039281A2 US 2005034619 W US2005034619 W US 2005034619W WO 2006039281 A2 WO2006039281 A2 WO 2006039281A2
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
sunscreen
skin
sun product
topical
Prior art date
Application number
PCT/US2005/034619
Other languages
English (en)
Other versions
WO2006039281A3 (fr
Inventor
John R. Person
Original Assignee
Person John R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/956,993 external-priority patent/US20060073107A1/en
Priority claimed from US11/053,432 external-priority patent/US20060177390A1/en
Priority claimed from US11/196,946 external-priority patent/US20100093674A1/en
Application filed by Person John R filed Critical Person John R
Publication of WO2006039281A2 publication Critical patent/WO2006039281A2/fr
Publication of WO2006039281A3 publication Critical patent/WO2006039281A3/fr
Priority to US13/017,610 priority Critical patent/US20110200542A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Definitions

  • the present invention relates to methods and products for preventing cancer through topical application of cancer inhibitors. More particularly, it relates to the use of sunscreens and after sun lotions and creams containing vitamin D 3 , vitamin D derivatives (natural or synthetic), or cod-liver oil to inhibit skin cancers and other dermatological disorders related to ultraviolet light exposure.
  • Non- melanoma basic and squamous cell carcinoma
  • sunscreens may reduce the incidence of nonmelanoma cancer.
  • Sunscreens seek to block the ultraviolet light, which causes sunburn and is a probable cause of skin cancers.
  • Sunscreens are rated with an sun-protective-factor (SPF) which is essentially a measure of protection against sunburn or ultraviolet B radiatioa
  • SPPF sun-protective-factor
  • High SPF sunscreens have been available for almost 30 years and broader spectrum sunscreens, which also block some longwave ultraviolet light, for almost 15 years.
  • SPDF sun-protective-factor
  • sunscreens may reduce the incidence of non-melanoma skin cancer, but it difficult to reconcile this with the non-melanoma skin cancer epidemic.
  • the situation with melanoma is less clear.
  • Some studies show a protective effect and others show that sunscreens may increase the risk of melanoma.
  • Basal cell carcinoma or melanoma So, testing of the effects of sunscreens with respectto skin cancer is difficult.
  • sunscreens inhibit epidermal synthesis of vitamin D 3 (cholecalciferol), and thatthis promotes the growth of cancer.
  • Calcitrol is a potent regulator of cell growth and differentiation. It also has an inhibitory effect on cellular death and new blood vessel growth, i.e., into tumors).
  • Low vitamin D levels have been associated with breast, prostate, and colon cancer.
  • New vitamin D analogues have been shown to be very effective in preventing chemical tumorgenesis in mice.
  • Vitamin D3 is synthesized by epidermal keratinocytes on exposure to UVB, but must undergo activation first by 25-hydroxylation and then 1 -alpha hydroxylation to convert it to 1,25 - dihydroxyvitamin D 3 , or calcitriol, the active form of vitamin D. Traditionally, these conversions have been thought to occur in the liver and kidney exclusively. Professor Michael F. Holick at Boston" University ' has suggestecl thaffhe UV blocking characteristics of sunscreens has inhibited the natural production of vitamin D3 by the skin. He has created a controversy among the dermatological community by suggesting some unprotected exposure to natural or artificial sunlight for short periods of time in order to increase vitamin D production. Additionally, he has several patents, such as U.S. Patent No.
  • the present invention provides a method of inhibiting skin cancers, precancers, photoaging and other dermatological disorders through use of vitamin D 3 .
  • vitamin D 3 is provided as an ingredient in a topical sunscreen.
  • cod-liver oil is provided as an ingredient in a topical sunscreen as a source of vitamin D 3 .
  • a topical sunscreen containing vitamin D 3 or cod-liver oil is applied to portions of the skin subjected to exposed to sunlight.
  • vitamin D 3 is provided as an ingredient in a topical lotion or cream associated with sun exposure.
  • cod-liver oil is provided as an ingredient in a topical lotion or cream associated with sun exposure as a source of vitamin D 3 .
  • a topical lotion or cream associated with sun exposure containing vitamin D 3 or cod-liver oil is applied to portions of the skin previously exposed to sunlight.
  • Vitamin D Metabolites By Human Melanoma Cells, J Clin Endocrimol Metab, 1983, 57:627-631. Polymorphisms of the vitamin D receptor are also associated with an increased susceptibility to and worsened progress in melanoma.
  • Halsall JA et al., A novel Polymorphism in the IA Promoter Region of the Vitamin D Receptor Is Associated With Altered Susceptibility and Prognosis in Malignant Melanoma, Br J Cancer, 2004: 16:765-70.
  • Hutchinson PE etal., Vitamin D Receptor Polymorphisms Are Associated With Altered Prognosis in Patients Wilh Melanoma, Clin Cancer Res.2000; 6:498-504.
  • Exposure to UV radiation can increase the risk of cancer.
  • it causes the skin to produce vitamin D which has a cancer inhibiting effect.
  • the use of sunscreens prevents me rormauon ot vitamin D in the skin Accordingly, protection against sunburn seems not to be protection against skin cancer due to variations in vitamin D formation and activation.
  • the present invention resolves the conflict by providing another source of vitamin D to the skin.
  • vitamin D 3 cholesterolcalciferol
  • other biologically active vitamin D derivatives are added to topical sunscreens. When the sunscreen is applied, it inhibits the UV radiation and its cancer causing effects.
  • the vitamin D 3 is provided to the skin.
  • the skin can activate the vitamin D 3 to calcitriol to provide the anti-cancer effects at the epidermis.
  • the benefits of vitamin D formation from UV radiation can be achieved without the harmful exposure.
  • the present invention includes other applications of vitamin D 3 or its derivatives.
  • topical products for use after exposure to the sun are generally in the form of lotions or creams containing aloe vera and other moisturizers for hydrating and protecting the skin from the exposure.
  • Other ingredients are also used to maintain the skin, sooth minor burns, and prevent peeling.
  • Many people use these formulations to protect and preserve their skin when they have ordinary or excessive exposure to the sun. They can also provide an opportunity to help prevent skin cancer.
  • the addition of vitamin D 3 to such formulations provides for application of vitamin D 3 to the skin where it provides its cancer inhibiting effects.
  • vitamin D 3 The amount and form for adding vitamin D 3 to topical sunscreens or after sun lotions in order to best achieve the benefits is still subject to research and testing.
  • synthetic or natural sources of vitamin D 3 such as cod-liver oil
  • the topical application of vitamin D is safe and beneficial.
  • Vitamins A, E, and C are currently added to some sunscreens.
  • various vitamins, herbs and other ingredients are added to after sun lotions.
  • vitamin D 3 could also be added Since vitamin D 3 is lipid soluble, the sunscreen or after sun lotion should contain lipids. Otherwise, any sunscreen or after sun formulation can be used with the present invention.
  • vitamin D and its analogs are of potential benefit in the treatment of photoaging. Nagpal S, et al. Vitamin D analogs: mechanism of action and therapeutic applications. CurrMedChem2001; 8: 1661-79. Thus, the addition of vi ⁇ a ⁇ un u 3 ⁇ sunscreen or a ⁇ er sun iouons may also inhibit photoaging.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)

Abstract

Une plus grande utilisation de crèmes solaires, tout en limitant les dommages à l'ADN, peut favoriser la croissance du cancer en évitant la synthèse de vitamine D dans la peau. Selon cette invention, les effets bénéfiques des rayonnements UV sont obtenus par incorporation de vitamine D dans la crème solaire topique ou des lotions après-solaires. L'application de crème solaire protège contre les effets néfastes des rayonnements UV et la vitamine D y étant contenue est activée par la peau en calcitriol afin de prévenir le cancer. Etant donné que le calcitriol favorise également la croissance et la différenciation cellulaire, la crème solaire topique ou le produit après-solaire contenant de la vitamine D peut être bénéfique contre le photovieillissement.
PCT/US2005/034619 2004-09-29 2005-09-29 Produit et procede de prevention du cancer de la peau WO2006039281A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/017,610 US20110200542A1 (en) 2004-10-04 2011-01-31 Skin cancer prevention method and product

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/956,993 2004-09-29
US10/956,993 US20060073107A1 (en) 2004-10-04 2004-10-04 Use of vitamin D3 (cholecalciferol) in sunscreens
US11/053,432 US20060177390A1 (en) 2005-02-08 2005-02-08 Skin cancer prevention method and product
US11/053,432 2005-02-08
US11/196,946 US20100093674A1 (en) 2005-08-04 2005-08-04 Skin cancer prevention method and product
US11/196,946 2005-08-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/196,946 Continuation US20100093674A1 (en) 2004-09-29 2005-08-04 Skin cancer prevention method and product

Publications (2)

Publication Number Publication Date
WO2006039281A2 true WO2006039281A2 (fr) 2006-04-13
WO2006039281A3 WO2006039281A3 (fr) 2006-07-06

Family

ID=36143667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/034619 WO2006039281A2 (fr) 2004-09-29 2005-09-29 Produit et procede de prevention du cancer de la peau

Country Status (1)

Country Link
WO (1) WO2006039281A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156608A1 (fr) * 2016-03-15 2017-09-21 Luiz Francisco Pianowski Produit de protection solaire et procédé d'application de produit de protection solaire sur la peau
WO2018141988A1 (fr) * 2017-02-06 2018-08-09 3Skin As Composition d'écran solaire
WO2021033003A1 (fr) * 2019-08-22 2021-02-25 Industrial Technologies & Biotechnologies Hormone d (vitamine d) et ses dérivés pour le traitement et la prévention du cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422099A (en) * 1990-06-21 1995-06-06 Trustees Of Boston University Compositions comprising vitamin D precursors and the use thereof
US5804574A (en) * 1996-01-03 1998-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs useful for reversing the photodamage in sun-exposed skin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422099A (en) * 1990-06-21 1995-06-06 Trustees Of Boston University Compositions comprising vitamin D precursors and the use thereof
US5804574A (en) * 1996-01-03 1998-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs useful for reversing the photodamage in sun-exposed skin

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156608A1 (fr) * 2016-03-15 2017-09-21 Luiz Francisco Pianowski Produit de protection solaire et procédé d'application de produit de protection solaire sur la peau
WO2018141988A1 (fr) * 2017-02-06 2018-08-09 3Skin As Composition d'écran solaire
CN110325246A (zh) * 2017-02-06 2019-10-11 3Skin有限公司 防晒组合物
AU2018216043B2 (en) * 2017-02-06 2020-02-27 3Skin As Sunscreen composition
EP3725374A1 (fr) * 2017-02-06 2020-10-21 3Skin AS Composition d'écran solaire
CN110325246B (zh) * 2017-02-06 2022-07-05 3Skin有限公司 防晒组合物
WO2021033003A1 (fr) * 2019-08-22 2021-02-25 Industrial Technologies & Biotechnologies Hormone d (vitamine d) et ses dérivés pour le traitement et la prévention du cancer

Also Published As

Publication number Publication date
WO2006039281A3 (fr) 2006-07-06

Similar Documents

Publication Publication Date Title
Burke et al. Effects of topical and oral vitamin E on pigmentation and skin cancer induced by ultraviolet irradiation in Skh: 2 hairless mice
JP6313791B2 (ja) 皮膚科学的使用のためのレゾルシノール化合物
EP0918504B1 (fr) Utilisation de la genisteine comme agent preventif contre les dommages cutanes et les cancers de la peau induits par les rayons ultraviolets
TWI679992B (zh) 局部美白組合物及其使用方法
Wertz et al. β-carotene interferes with ultraviolet light A-induced gene expression by multiple pathways
JP5675112B2 (ja) アルクチン、アルクチゲニン又はその混合物を有効成分として含有する皮膚美白用化粧料組成物
Kira et al. Vitamin D and the skin
JP2013506623A (ja) ストレスに曝されて改変された酵母エキスおよびこれに関連する組成物の化粧品としての使用
KR20130035325A (ko) 차나무 뿌리 유래 사포닌을 함유하는 피부 외용제 조성물
Segars et al. Dermatologic applications of polypodium leucotomos: a literature review
US20110200542A1 (en) Skin cancer prevention method and product
JP2010535758A (ja) ジオスゲニンを含む皮膚美白用組成物
WO2006039281A2 (fr) Produit et procede de prevention du cancer de la peau
Kumar et al. Photoprotective effect of 18β-glycyrrhetinic acid derivatives against ultra violet (UV)-B-Induced skin aging
US20060177390A1 (en) Skin cancer prevention method and product
US20100093674A1 (en) Skin cancer prevention method and product
EP2772255B1 (fr) Composition comprenant du syringarésinol pour améliorer la peau
JP2008208073A (ja) メラニン産生抑制剤及び皮膚外用剤
Tang et al. Vitamin D and skin cancer
US20150202130A1 (en) Cosmetic use of salicylic acid derivatives
KR100924060B1 (ko) 퓨린 유도체를 포함하는 멜라닌 생성 촉진 조성물
Nautiyal et al. Deciphering the role of vitamin D on skin cancers and tumour microenvironment
KR20180068914A (ko) 시링가레시놀을 포함하는 노화 억제용 조성물
ES2668848T3 (es) Mezcla para la inhibición de biosíntesis de melanina
EP1230924A1 (fr) Medicaments contre la proliferation des melanocytes et pour la pigmentation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05802090

Country of ref document: EP

Kind code of ref document: A2